ALDH3A1抗体

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane 1-2: A549 cells, mouse eye tissue, Primary antibody: P07812(ALDH3A1 Antibody) at dilution 1/750, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gasrtic cancer tissue using P07812(ALDH3A1 Antibody) at dilution 1/55. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P07812(ALDH3A1 Antibody) at dilution 1/55. (Original magnification: ×200)    

  
  

ALDH3A1 (aldehyde dehydrogenase 3 family member A1) is a member of the aldehyde dehydrogenase superfamily, which plays a critical role in detoxifying endogenous and exogenous aldehydes, lipid peroxidation products, and reactive oxygen species (ROS). This enzyme is highly expressed in tissues such as the liver, stomach, cornea, lung, and certain cancer cells. It contributes to cellular defense against oxidative stress, metabolic regulation, and drug resistance mechanisms. ALDH3A1 also exhibits non-enzymatic chaperone-like functions, protecting proteins from UV-induced damage.

Antibodies targeting ALDH3A1 are widely used in research to study its expression, localization, and functional roles. They enable detection via techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry. Commercially available ALDH3A1 antibodies are typically developed using recombinant protein fragments or synthetic peptides, with validation across human, mouse, and rat samples. Both monoclonal and polyclonal formats exist, offering specificity or broader cross-reactivity depending on research needs.

Research applications focus on ALDH3A1's involvement in diseases, including cancer (e.g., resistance to chemotherapeutics in gliomas or breast cancer), corneal transparency disorders, and inflammatory conditions. Its overexpression in tumors has been linked to poor prognosis, making it a potential biomarker for therapeutic targeting. Antibody-based studies also explore ALDH3A1's role in metabolic pathways and oxidative stress responses, aiding drug development and mechanistic understanding of cellular resilience.